Masimo (NASDAQ:MASI) Issues Q3 Earnings Guidance

Masimo (NASDAQ:MASI) updated its third quarter earnings guidance on Wednesday. The company provided EPS guidance of $0.81-0.86 for the period, compared to the consensus EPS estimate of $0.84. The company issued revenue guidance of $495-515 million, compared to the consensus revenue estimate of $502.48 million.

Masimo Stock Performance

Shares of MASI opened at $126.18 on Wednesday. The firm has a fifty day moving average of $115.66 and a 200-day moving average of $124.85. The company has a market cap of $6.71 billion, a price-to-earnings ratio of 85.84 and a beta of 0.98. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.15 and a current ratio of 2.09. Masimo has a 1 year low of $75.22 and a 1 year high of $153.93.

Masimo (NASDAQ:MASI) last posted its earnings results on Tuesday, August 6th. The medical equipment provider reported $0.86 EPS for the quarter, topping the consensus estimate of $0.77 by $0.09. The firm had revenue of $496.30 million during the quarter, compared to analysts’ expectations of $493.92 million. Masimo had a net margin of 3.94% and a return on equity of 14.07%. Masimo’s quarterly revenue was up 9.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.62 EPS. As a group, equities analysts anticipate that Masimo will post 3.87 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Piper Sandler boosted their price target on Masimo from $160.00 to $165.00 and gave the stock an overweight rating in a research report on Wednesday, August 7th. Needham & Company LLC restated a hold rating on shares of Masimo in a research note on Friday, September 20th. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, Masimo has an average rating of Moderate Buy and an average price target of $144.67.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.